Abstract
Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have been recognized as anchor drugs for treating advanced melanoma, with or without additional combination drugs such as ipilimumab, but the efficacies of these immunotherapies are not fully satisfactory. In this review, we describe the development of the currently available anti-PD1 Abs-based immunotherapies for advanced melanoma, focusing on their efficacy and immune-related adverse events (AEs), as well as clinical trials still ongoing for the future treatment of advanced melanoma.
Funder
Japan Agency for Medical Research and Development
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference94 articles.
1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma;Larkin;N. Engl. J. Med.,2015
2. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma;Larkin;N. Engl. J. Med.,2019
3. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021;Swetter;J. Natl. Compr. Cancer Netw.,2021
4. Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019;Nakamura;J. Dermatol.,2020
5. Fujimura, T., Kambayashi, Y., Ohuchi, K., Muto, Y., and Aiba, S. (2020). Treatment of Advanced Melanoma: Past, Present and Future. Life, 10.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献